ChromaDex is one step closer to regulatory approval in the European Union with this positive opinion from the European Food Safety Authority.
Photo © Shutterstock.com/AlexLMX
ChromaDex Corp. announced that the European Food Safety Authority (EFSA) issued a positive opinion on nicotinamide riboside (NR) as a novel food ingredient for use in food supplements, at a serving of 300 mg daily, for the healthy adult population. Now NR will advance to the European Commission for review. Once the regulatory process for the European market is complete, ChromaDex plans to launch its flagship NR product Tru Niagen in the European Union (EU).
“Safety is paramount for ChromaDex and this positive opinion from EFSA underscores our depth of science, and is the latest in a consistently positive series of reviews of NR by authoritative bodies,” said ChromaDex CEO Rob Fried, in a press release. “We are diligently working to complete the regulatory process to bring NR to the health-conscious people of the EU.”
FDA revokes authorization to use Red No. 3 as a color additive in food or drugs
January 15th 2025FDA contends that the color additive is safe for humans but is legally obligated by the Delaney Clause of the FD&C act to revoke authorization as research shows the Red No. 3 induces cancer in rats.
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.
FDA revokes authorization to use Red No. 3 as a color additive in food or drugs
January 15th 2025FDA contends that the color additive is safe for humans but is legally obligated by the Delaney Clause of the FD&C act to revoke authorization as research shows the Red No. 3 induces cancer in rats.
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.
2 Commerce Drive
Cranbury, NJ 08512